These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12668861)

  • 1. The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
    Mayes CE; Kandzari DE; Goldschmidt-Clermont PJ; Phillips HR
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():36E-46E; quiz 47E. PubMed ID: 12668861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
    Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
    J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
    Tcheng JE
    Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB
    J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
    Teirstein PS; Kao J; Watkins M; Tannenbaum MA; Laufer N; Chang M; Mehran R; Dangas G; Russell ME; Ellis SG; Stone GW
    Am J Cardiol; 2005 Aug; 96(4):500-5. PubMed ID: 16098300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
    Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
    J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ; Topol EJ
    Am Heart J; 2000 Nov; 140(5):722-6. PubMed ID: 11054616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
    Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
    Dangas G; Colombo A
    Am Heart J; 1999 Jul; 138(1 Pt 2):S16-23. PubMed ID: 10385787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB; Newman AR; Raco DL
    Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM
    Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.